Roth Capital Affirms Peregrine at BUY; Remains Encouraged by Progress in FY14...
July 15, 2014 9:56amET “Roth Capital affirms its Buy rating and $5 price target on Peregrine Pharmaceuticals (Nasdaq: PPHM) following Q2 results issued after...” (prem. membership only) http://www.streetinsider.com/stock_lookup.php?q=PPHM